Experimental 'Storm Stopper' therapy tested for COVID, flu, and RSV
NCT ID NCT06684379
First seen Jun 10, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This early-stage trial tests a new drug called PRS CK STORM, made from immune and fat cells, to see if it can safely calm the 'cytokine storm'—a dangerous overreaction of the immune system—in people with severe COVID-19, flu, or RSV who need oxygen. About 50 adults will receive one of two doses or a placebo. The main goals are to check safety and to see if the treatment reduces inflammation and improves oxygen levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitario Príncipe de Asturias
RECRUITINGAlcalá de Henares, Madrid, 28805, Spain
Contact
-
Hospital Universitario Reina Sofía
RECRUITINGCórdoba, 14004, Spain
Contact
-
Hospital Universitario de Fuenlabrada
RECRUITINGFuenlabrada, Madrid, 28942, Spain
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRS CK STORM (a liquid made from immune and fat cells)
What this could lead to
If it works, this could offer a new way to calm the dangerous overreaction of the immune system (cytokine storm) in severe respiratory infections.
What could go wrong
This is a very early, small trial (50 people) testing safety and dosing. It may not show clear benefit, and the treatment is still experimental.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.